Quantcast
Last updated on April 17, 2014 at 11:49 EDT

Latest Naltrexone Stories

2014-04-16 16:30:50

DUBLIN, April 16, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/q7jzmk/sustained_release) has announced the addition of the "Concise Analysis of International Sustained Release Injectables to 2020" [http://www.researchandmarkets.com/research/q7jzmk/sustained_release ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Formulations, Dosing, Devices, Markets and Forecasts The ability...

2014-04-04 08:24:45

-- Clinically meaningful improvement in quality of life with single injection of resiniferatoxin SAN DIEGO, April 4, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that investigators from the National Institutes of Health (NIH) presented data highlighting results from the first two dosing cohorts of the Phase I/II trial of...

2014-04-03 12:29:12

NEW YORK, April 3, 2014 /PRNewswire/ -- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on BioCorRx Inc. BioCorRx Inc. (OTCQB: BICX) offers a comprehensive and cost-effective recovery program for the treatment of alcoholism called the Start Fresh Program which the company believes incorporates all of the essential elements for successful alcohol addiction recovery. The Start Fresh Program is designed to treat and to heal...

2014-03-11 16:26:19

PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including...

2014-03-06 12:27:02

ORLANDO, Fla., March 6, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK). TNI BioTech has spent the last year developing a manufacturing and distribution network for sale of LDN into emerging nations and has had discussions with the FDA and EMA to begin clinical trials in the United States. The Company has considered whether to...

2014-02-11 08:25:00

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5nldqw/sustained_release ) has announced the addition of the "Sustained Release Injectables to 2020" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Formulations, Dosing, Devices, Markets and Forecasts The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency...

2014-01-29 12:28:05

NEW YORK, Jan. 29, 2014 /PRNewswire/ -- Fresh Start Private Management, Inc. (OTCQB: CEYY) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a highly effective program consisting of two components used by alcohol addiction clinics in the US. Clinic reports show that the treatment program has an 85% success rate with individuals that complete the program. The first component of the program consists of an outpatient...

2014-01-28 23:31:20

One of the top New Year’s resolutions for both men and women is to stay sober during the New Year. Whether struggling with an addiction to drugs or alcohol, anyone can benefit from Synergy Lifestyle Center’s comprehensive addiction treatment program, which features the effective combination of medical treatment and counseling services. (PRWEB) January 28, 2014 Synergy Lifestyle Center offers an addiction treatment program that helps patients who have committed to sobriety in the New...

2014-01-07 08:30:44

SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that the United States Food and Drug Administration (FDA) considers the recent resubmission of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application to be a complete response to the FDA's prior January 31, 2011 action letter. For the resubmission, the FDA has assigned a Prescription Drug User Fee Act goal date of June 10, 2014. If approved, the Company...

2014-01-04 23:24:08

Aid in Recovery released a statement today commenting on a recent study into the effectiveness of Naltrexone in treating addiction to opioids. Aid in Recovery has said that it will stay abreast of all clinical research regarding this drug, in order to better serve their patients. West Palm Beach, Florida (PRWEB) January 03, 2014 Aid in Recovery released a statement today commenting on recent research into the effectiveness of the drug Nalltrexone in the treatment of opiod addiction. The...